CoChat

Senolytics reduce coronavirus-related mortality in old mice

Open access

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Abstract

Senescent cells exacerbate COVID-19: Cellular senescence is a state elicited in response to stress signals and is associated with a damaging secretory phenotype. The number of senescent cells increases with advanced age and this in turn drives age-related diseases. Camell et al. show that senescent cells have an amplified inflammatory response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (see the Perspective by Cox and Lord). This response is communicated to nonsenescent cells, suppressing viral defense mechanisms and increasing the expression of viral entry proteins. In old mice infected with a SARS-CoV-2–related virus, treatment with senolytics to reduce the senolytic cell burden reduced mortality and increased antiviral antibodies. Science , abe4832, this issue p. eabe4832 ; see also abi4474, p. 281

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/science.abe4832

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Figures

SnCs that accumulate with age or chronic disease react to PAMPs such as SARS-CoV-2 S1 by amplifying the SASP, which increases viral entry protein expression and decreases viral defense IFITMs in normal cells. Old mice exposed to pathogens such as the β-coronavirus MHV have increased inflammation and higher mortality. Treatment with a senolytic decreased SnCs, inflammation, and mortality and increased the antiviral antibody response.
SnCs that accumulate with age or chronic disease react to PAMPs such as SARS-CoV-2 S1 by amplifying the SASP, which increases viral entry protein expression and decreases viral defense IFITMs in normal cells. Old mice exposed to pathogens such as the β-coronavirus MHV have increased inflammation and higher mortality. Treatment with a senolytic decreased SnCs, inflammation, and mortality and increased the antiviral antibody response.CC BY · PubMed Central
Fig. 1 The SASP is amplified by PAMP factors. (A) Human adipocyte progenitors isolated from subcutaneous fat biopsies were induced to undergo senescence with 10 gray (Gy) of ionizing radiation (SnC) or not (non-SnC) (n = 5 subjects). Cells were treated with 10 ng of the prototype PAMP LPS for 3 hours before RNA isolation. Gene expression was measured with quantitative PCR, and the expression in LPS-treated cells was normalized to vehicle-treated samples. Means ± SEM. Statistical significance was calculated by using a mixed effect model for the effect of LPS on SnCs and its differential effects on SnCs compared with non-SnCs. Details are available in table S1. Arrows and asterisks: gray, vehicle-treated SnCs versus non-SnCs; black, LPS-treated SnCs versus non-SnCs; red, SnCs ± LPS. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (B) Young (2-month-old) and old (26-month-old) mice were treated with phosphate-buffered saline (PBS) (n = 5 young and 5 old) or LPS (n = 4 young and 3 old), and tissues were collected 24 hours later. RNA was isolated from liver, and gene expression measured by means of quamtitative PCR. Expression in LPS-treated mice was normalized to vehicle-treated animals. Means ± SEM, two-way analysis of variance (ANOVA) and post hoc comparison Tukey’s honestly significant difference used to compare the two animal cohorts within a treatment group. Arrows and asterisks: gray, vehicle-treated old versus young; black, LPS-treated old versus young; red, old ± LPS. **P < 0.01, ***P < 0.001, ****P < 0.0001. Kidney data are provided in fig. S2. (C) Serum protein from the same mice measured with enzyme-linked immunosorbent assay (ELISA). Statistics are as described in (B).
Fig. 1 The SASP is amplified by PAMP factors. (A) Human adipocyte progenitors isolated from subcutaneous fat biopsies were induced to undergo senescence with 10 gray (Gy) of ionizing radiation (SnC) or not (non-SnC) (n = 5 subjects). Cells were treated with 10 ng of the prototype PAMP LPS for 3 hours before RNA isolation. Gene expression was measured with quantitative PCR, and the expression in LPS-treated cells was normalized to vehicle-treated samples. Means ± SEM. Statistical significance was calculated by using a mixed effect model for the effect of LPS on SnCs and its differential effects on SnCs compared with non-SnCs. Details are available in table S1. Arrows and asterisks: gray, vehicle-treated SnCs versus non-SnCs; black, LPS-treated SnCs versus non-SnCs; red, SnCs ± LPS. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (B) Young (2-month-old) and old (26-month-old) mice were treated with phosphate-buffered saline (PBS) (n = 5 young and 5 old) or LPS (n = 4 young and 3 old), and tissues were collected 24 hours later. RNA was isolated from liver, and gene expression measured by means of quamtitative PCR. Expression in LPS-treated mice was normalized to vehicle-treated animals. Means ± SEM, two-way analysis of variance (ANOVA) and post hoc comparison Tukey’s honestly significant difference used to compare the two animal cohorts within a treatment group. Arrows and asterisks: gray, vehicle-treated old versus young; black, LPS-treated old versus young; red, old ± LPS. **P < 0.01, ***P < 0.001, ****P < 0.0001. Kidney data are provided in fig. S2. (C) Serum protein from the same mice measured with enzyme-linked immunosorbent assay (ELISA). Statistics are as described in (B).CC BY · PubMed Central
Fig. 2 The SARS-CoV2 spike protein-1 (S1) exacerbates the secretory phenotype of senescent human endothelial cells, decreasing viral defenses and elevating viral entry/processing gene expression. (A) Primary human kidney endothelial cells (n = 9 biological replicates) were induced to undergo senescence with 10 Gy of ionizing radiation (SnC) or not (non-SnC) then treated with 500 ng recombinant S1 or PBS vehicle for 24 hours. Thirty SASP-related proteins were measured in the conditioned media (CM) by means of Luminex xMAP technology. Relative abundance induced by S1, normalized to vehicle treated non-SnCs (non-SnC + Veh), is illustrated in the heat map. A mixed effects model was used to test the effect of S1, senescence, and their interaction, taking into account duplicate measures within a subject for each protein as well as the composite score. Margin effects of SnCs in the treatment group also were tested under the mixed-effects model framework. Overall, the effect of S1 on SnCs was significantly more pronounced than on non-SnCs (composite score change P < 0.0089; mean values and P values for each cytokine are in table S2). (B) Schematic of experiments in (C), (E), and (F). Primary human cells were induced to undergo senescence with 10 Gy of ionizing radiation (SnC) or not (non-SnC). Twenty days later, CM was collected (n = 4 biological replicates) and used to treat non-SnCs (n = 4 biological replicates) either with or without neutralizing antibodies to IL-1α, IL-18, and PAI-1 (alone or in combination) for 48 hours, then RNA was isolated to measure expression of genes related to SARS-CoV-2 pathogenesis by means of quantitative PCR. Expression in cells treated with SnC CM was normalized to cells treated with non-SnC CM. Data are displayed as mean ± SEM, mixed-effects model. *P < 0.05 **P < 0.01, ***P < 0.001, ****P < 0.0001. (C) IFITM expression in human kidney endothelial cells treated with CM from SnC versus non-SnC human kidney endothelial cells. (D) IFITM expression in human kidney endothelial cells exposed to two concentrations of IL-1α (n = 4 biological replicates). Expression was normalized to vehicle-treated samples. (E) Gene expression in human lung epithelial cells treated with CM from SnC versus non-SnC preadipocytes, HUVECs, or kidney endothelial cells. (F) TMPRSS2 expression in human kidney endothelial cells treated with CM from SnC versus non-SnC kidney endothelial cells with or without neutralizing antibodies or human kidney endothelial cells with recombinant IL-1α for 48 hours. (G) Human lung biopsies acquired for clinical indications of focal, noninfectious causes from elderly patients were stained for TMPRSS2, p16INK4a, and 4′,6-diamidino-2-phenylindole (DAPI) to detect nuclei (n = 5 subjects). Representative images are shown. Scale bar, 20 μm. (H) TMPRSS2+, p16INK4a+, and total nuclei were counted and expressed as a function of total nuclei in each field. TMPRSS2+ and p16INK4a+ cells/field were tightly linked (P < 0.0001; partial Pearson correlation). Each color series of dots indicates replicates from a single subject.
Fig. 2 The SARS-CoV2 spike protein-1 (S1) exacerbates the secretory phenotype of senescent human endothelial cells, decreasing viral defenses and elevating viral entry/processing gene expression. (A) Primary human kidney endothelial cells (n = 9 biological replicates) were induced to undergo senescence with 10 Gy of ionizing radiation (SnC) or not (non-SnC) then treated with 500 ng recombinant S1 or PBS vehicle for 24 hours. Thirty SASP-related proteins were measured in the conditioned media (CM) by means of Luminex xMAP technology. Relative abundance induced by S1, normalized to vehicle treated non-SnCs (non-SnC + Veh), is illustrated in the heat map. A mixed effects model was used to test the effect of S1, senescence, and their interaction, taking into account duplicate measures within a subject for each protein as well as the composite score. Margin effects of SnCs in the treatment group also were tested under the mixed-effects model framework. Overall, the effect of S1 on SnCs was significantly more pronounced than on non-SnCs (composite score change P < 0.0089; mean values and P values for each cytokine are in table S2). (B) Schematic of experiments in (C), (E), and (F). Primary human cells were induced to undergo senescence with 10 Gy of ionizing radiation (SnC) or not (non-SnC). Twenty days later, CM was collected (n = 4 biological replicates) and used to treat non-SnCs (n = 4 biological replicates) either with or without neutralizing antibodies to IL-1α, IL-18, and PAI-1 (alone or in combination) for 48 hours, then RNA was isolated to measure expression of genes related to SARS-CoV-2 pathogenesis by means of quantitative PCR. Expression in cells treated with SnC CM was normalized to cells treated with non-SnC CM. Data are displayed as mean ± SEM, mixed-effects model. *P < 0.05 **P < 0.01, ***P < 0.001, ****P < 0.0001. (C) IFITM expression in human kidney endothelial cells treated with CM from SnC versus non-SnC human kidney endothelial cells. (D) IFITM expression in human kidney endothelial cells exposed to two concentrations of IL-1α (n = 4 biological replicates). Expression was normalized to vehicle-treated samples. (E) Gene expression in human lung epithelial cells treated with CM from SnC versus non-SnC preadipocytes, HUVECs, or kidney endothelial cells. (F) TMPRSS2 expression in human kidney endothelial cells treated with CM from SnC versus non-SnC kidney endothelial cells with or without neutralizing antibodies or human kidney endothelial cells with recombinant IL-1α for 48 hours. (G) Human lung biopsies acquired for clinical indications of focal, noninfectious causes from elderly patients were stained for TMPRSS2, p16INK4a, and 4′,6-diamidino-2-phenylindole (DAPI) to detect nuclei (n = 5 subjects). Representative images are shown. Scale bar, 20 μm. (H) TMPRSS2+, p16INK4a+, and total nuclei were counted and expressed as a function of total nuclei in each field. TMPRSS2+ and p16INK4a+ cells/field were tightly linked (P < 0.0001; partial Pearson correlation). Each color series of dots indicates replicates from a single subject.CC BY · PubMed Central
Fig. 3 Old mice are vulnerable to a NME that includes acute mouse β-coronavirus infection. (A) Young (3-month-old) and old (20- to 24-month-old) WT mice were exposed to NME bedding produced from pet store mice for 7 days. Survival was monitored for 35 days after initiation of NME (n = 10 young; n = 18 old). Log-rank (Mantel Cox) test. (B) Gene expression in three tissues of SPF or NME (6- to 7-day exposure) young and old mice (n = 3 young SPF; n = 5 old SPF; n = 14 young NME; n = 13 old NME) measured with quantitative PCR. Expression was normalized to young SPF mice. Means ± SEM, two-way ANOVA and post hoc comparison Tukey’s honestly significant difference were used to compare the two animal cohorts within a treatment group. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Arrows and asterisks: gray, SPF old versus young; black, NME old versus young; red, old SPF versus old NME. (C) Serum cytokine levels in young and old mice (n = 3 young SPF; n = 5 old SPF; n = 19 young NME; n = 17 old NME) measured with ELISA at day 5 after NME. Statistics are as described in (B). (D) Serology to detect antibodies against microbes in NME bedding. (Right) The mouse pathogens commonly tested for by Charles River Laboratory to define SPF housing. The pie charts illustrate the exposures detected in individual young and old mice (n = 24 young; n = 21 to 23 old) day 11 after initiation of NME. Serology of pet store mice is illustrated below. (E) Representative images of hematoxylin and eosin (H&E) staining or MHV immunohistochemistry in liver sections from young and old mice exposed to NME. (F) (Top) Schematic to illustrate the experimental design. Young (6-month-old) or old (22-month-old) female mice were inoculated with a sublethal dose of MHV. Thirty days later, naïve and inoculated mice were exposed to NME bedding for 3 weeks. (Bottom) Serum antibodies against three different MHV antigens measured 21 days after MHV inoculation and reported as relative scores. The dotted line indicates the limit of detection (LOD). Means ± SEM, unpaired two-tailed Student’s t test. **P < 0.01, ****P < 0.0001. (G) Survival of MHV-inoculated and naïve mice measured for 42 days after initiation of NME. Log-rank (Mantel Cox) test.
Fig. 3 Old mice are vulnerable to a NME that includes acute mouse β-coronavirus infection. (A) Young (3-month-old) and old (20- to 24-month-old) WT mice were exposed to NME bedding produced from pet store mice for 7 days. Survival was monitored for 35 days after initiation of NME (n = 10 young; n = 18 old). Log-rank (Mantel Cox) test. (B) Gene expression in three tissues of SPF or NME (6- to 7-day exposure) young and old mice (n = 3 young SPF; n = 5 old SPF; n = 14 young NME; n = 13 old NME) measured with quantitative PCR. Expression was normalized to young SPF mice. Means ± SEM, two-way ANOVA and post hoc comparison Tukey’s honestly significant difference were used to compare the two animal cohorts within a treatment group. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Arrows and asterisks: gray, SPF old versus young; black, NME old versus young; red, old SPF versus old NME. (C) Serum cytokine levels in young and old mice (n = 3 young SPF; n = 5 old SPF; n = 19 young NME; n = 17 old NME) measured with ELISA at day 5 after NME. Statistics are as described in (B). (D) Serology to detect antibodies against microbes in NME bedding. (Right) The mouse pathogens commonly tested for by Charles River Laboratory to define SPF housing. The pie charts illustrate the exposures detected in individual young and old mice (n = 24 young; n = 21 to 23 old) day 11 after initiation of NME. Serology of pet store mice is illustrated below. (E) Representative images of hematoxylin and eosin (H&E) staining or MHV immunohistochemistry in liver sections from young and old mice exposed to NME. (F) (Top) Schematic to illustrate the experimental design. Young (6-month-old) or old (22-month-old) female mice were inoculated with a sublethal dose of MHV. Thirty days later, naïve and inoculated mice were exposed to NME bedding for 3 weeks. (Bottom) Serum antibodies against three different MHV antigens measured 21 days after MHV inoculation and reported as relative scores. The dotted line indicates the limit of detection (LOD). Means ± SEM, unpaired two-tailed Student’s t test. **P < 0.01, ****P < 0.0001. (G) Survival of MHV-inoculated and naïve mice measured for 42 days after initiation of NME. Log-rank (Mantel Cox) test.CC BY · PubMed Central
Fig. 4 Treatment with the senolytic fisetin decreases mortality in NME-exposed old mice. (A) Schematic of the experiment. Young (6 to 7 months) and old (20 to 24 months) mice were exposed to NME bedding containing mouse β-coronavirus MHV for 7 days. Mice were treated with 20 mg/kg/day Fisetin or vehicle only by means of oral gavage daily for 3 consecutive days starting on day 3 after initiation of NME. The 3 days of treatment were repeated (3 days on, 4 days off) for 3 weeks. Animals were also fed standard chow with Fisetin added (500 ppm) ad libitum after initiation of treatment. (B) Survival was measured for 36 days after initiation of NME (n = 9 young + vehicle; n = 5 young + Fisetin; n = 18 old + vehicle; n = 19 old + Fisetin). Log-rank (Mantel Cox) test. P < 0.0001 for old mice ± Fisetin. (C) Relative MHV antibody score in young and old mice in (B) on the indicated day after initiation of NME. (D to G) Young (2-month-old) and old (20-month-old) mice were exposed to NME bedding ± treatment with Fisetin as described in (A). On days 8 to 9 after initiation of NME, animals were euthanized, and tissues collected for measuring gene expression (n = 10 young + vehicle; n = 8 to 10 young + Fisetin; n = 10 to 11 old + vehicle; n = 13 old + Fisetin). All expression data were normalized to young mice treated with vehicle. Data are displayed as means ± SEM, two-way ANOVA and post-hoc comparison Tukey’s honestly significant difference used to compare the two animal cohorts within a treatment group. Arrows and asterisks: gray, vehicle-treated old versus young; black, Fisetin-treated old versus young; red, old ± Fisetin. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (D) MHV mRNA was quantified by means of quantitative PCR in fecal pellets collected from individual animals in (C). (E) Quantification of p16Ink4a and p21Cip1 mRNA in four tissues. (F) Quantification of SASP factor mRNA in liver. Data on other genes and tissues are available in fig. S9. (G) SASP protein levels in the liver measured with ELISA.
Fig. 4 Treatment with the senolytic fisetin decreases mortality in NME-exposed old mice. (A) Schematic of the experiment. Young (6 to 7 months) and old (20 to 24 months) mice were exposed to NME bedding containing mouse β-coronavirus MHV for 7 days. Mice were treated with 20 mg/kg/day Fisetin or vehicle only by means of oral gavage daily for 3 consecutive days starting on day 3 after initiation of NME. The 3 days of treatment were repeated (3 days on, 4 days off) for 3 weeks. Animals were also fed standard chow with Fisetin added (500 ppm) ad libitum after initiation of treatment. (B) Survival was measured for 36 days after initiation of NME (n = 9 young + vehicle; n = 5 young + Fisetin; n = 18 old + vehicle; n = 19 old + Fisetin). Log-rank (Mantel Cox) test. P < 0.0001 for old mice ± Fisetin. (C) Relative MHV antibody score in young and old mice in (B) on the indicated day after initiation of NME. (D to G) Young (2-month-old) and old (20-month-old) mice were exposed to NME bedding ± treatment with Fisetin as described in (A). On days 8 to 9 after initiation of NME, animals were euthanized, and tissues collected for measuring gene expression (n = 10 young + vehicle; n = 8 to 10 young + Fisetin; n = 10 to 11 old + vehicle; n = 13 old + Fisetin). All expression data were normalized to young mice treated with vehicle. Data are displayed as means ± SEM, two-way ANOVA and post-hoc comparison Tukey’s honestly significant difference used to compare the two animal cohorts within a treatment group. Arrows and asterisks: gray, vehicle-treated old versus young; black, Fisetin-treated old versus young; red, old ± Fisetin. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (D) MHV mRNA was quantified by means of quantitative PCR in fecal pellets collected from individual animals in (C). (E) Quantification of p16Ink4a and p21Cip1 mRNA in four tissues. (F) Quantification of SASP factor mRNA in liver. Data on other genes and tissues are available in fig. S9. (G) SASP protein levels in the liver measured with ELISA.CC BY · PubMed Central
Fig. 5 Pharmacologic and genetic ablation of SnCs reduces mortality in old mice exposed to NME. (A) Schematic diagram of the experimental design for (B) to (D). Young (4-month-old) and old (22- to 30-month-old) male and female INK-ATTAC mice were treated with vehicle or AP20187 (n = 10 young; n = 19 old + vehicle; n = 19 old + AP20187) to dimerize FKBP-caspase-8 fusion protein expressed in p16Ink4a+ cells to kill SnC selectively. AP20187 (10 mg/kg) or vehicle was administered intraperitoneally daily for 3 days starting 2 weeks before initiating NME and ending 1 week after (3 days on and 4 days). NME was started on day 0 and lasted 1 week. Mice housed in SPF conditions were used as controls. Tissues were collected 7 days after initiation of NME in another cohort of male animals for molecular analysis (n = 5 young ; n = 3 or 4 old + vehicle; n = 4 old + AP20187). (B) Quantification of MHV mRNA in fecal pellets isolated from individual mice. Means ± SEM, one-way ANOVA with Tukey’s test. **P < 0.01. (C) Quantification of eGFP (a reporter of p16Ink4a expression in the INK-ATTAC construct), p16Ink4a, and p21Cip1 mRNA in the kidney of mice in (B). All expression data were normalized to young mice treated with vehicle. Means ± SEM, one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001. (D) Survival of male and female mice measured for 30 days after initiation of NME. Log-rank (Mantel Cox) test. (E) Young (2-month-old, n = 5) and old (22-month-old, n = 10/group) female mice were exposed to NME bedding for 4 days. Beginning on day 3, mice were treated with 20 mg/kg Fisetin or 5 mg/kg Dasatinib plus 50 mg/kg Quercetin at days 3, 4, 11, and 12 by means of oral gavage, or with vehicle only. Survival was measured for 30 days after initiation of NME. Log-rank (Mantel Cox) test. (F) Survival curves for 20-month-old WT female mice (n = 10/treatment group) treated with 20 mg/kg Fisetin or vehicle by oral gavage on days 3 and 4 after initiation of NME exposure. Log-rank (Mantel Cox) test. (G) Survival of 22-month-old WT female mice (n = 9/treatment group) treated with 20 mg/kg Fisetin or vehicle only by oral gavage at days 3, 4, 10, and 11 after NME exposure monitored out to 60 days after exposure. Log-rank (Mantel Cox) test.
Fig. 5 Pharmacologic and genetic ablation of SnCs reduces mortality in old mice exposed to NME. (A) Schematic diagram of the experimental design for (B) to (D). Young (4-month-old) and old (22- to 30-month-old) male and female INK-ATTAC mice were treated with vehicle or AP20187 (n = 10 young; n = 19 old + vehicle; n = 19 old + AP20187) to dimerize FKBP-caspase-8 fusion protein expressed in p16Ink4a+ cells to kill SnC selectively. AP20187 (10 mg/kg) or vehicle was administered intraperitoneally daily for 3 days starting 2 weeks before initiating NME and ending 1 week after (3 days on and 4 days). NME was started on day 0 and lasted 1 week. Mice housed in SPF conditions were used as controls. Tissues were collected 7 days after initiation of NME in another cohort of male animals for molecular analysis (n = 5 young ; n = 3 or 4 old + vehicle; n = 4 old + AP20187). (B) Quantification of MHV mRNA in fecal pellets isolated from individual mice. Means ± SEM, one-way ANOVA with Tukey’s test. **P < 0.01. (C) Quantification of eGFP (a reporter of p16Ink4a expression in the INK-ATTAC construct), p16Ink4a, and p21Cip1 mRNA in the kidney of mice in (B). All expression data were normalized to young mice treated with vehicle. Means ± SEM, one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001. (D) Survival of male and female mice measured for 30 days after initiation of NME. Log-rank (Mantel Cox) test. (E) Young (2-month-old, n = 5) and old (22-month-old, n = 10/group) female mice were exposed to NME bedding for 4 days. Beginning on day 3, mice were treated with 20 mg/kg Fisetin or 5 mg/kg Dasatinib plus 50 mg/kg Quercetin at days 3, 4, 11, and 12 by means of oral gavage, or with vehicle only. Survival was measured for 30 days after initiation of NME. Log-rank (Mantel Cox) test. (F) Survival curves for 20-month-old WT female mice (n = 10/treatment group) treated with 20 mg/kg Fisetin or vehicle by oral gavage on days 3 and 4 after initiation of NME exposure. Log-rank (Mantel Cox) test. (G) Survival of 22-month-old WT female mice (n = 9/treatment group) treated with 20 mg/kg Fisetin or vehicle only by oral gavage at days 3, 4, 10, and 11 after NME exposure monitored out to 60 days after exposure. Log-rank (Mantel Cox) test.CC BY · PubMed Central
Fig. 6 SASP Amplifier/Rheostat hypothesis. Schematic of the hypothesis generated from these data and tested herein. SnC amplified the response to PAMPs in vitro and in vivo, resulting in increased production of pro-inflammatory cytokines and chemokines. This could exacerbate acute systemic inflammatory responses and cytokine release by innate immune cells and amplify the spread of senescence. This model could explain the increased risk of cytokine storm during COVID-19 or other infections and adverse outcomes observed in the elderly or those with chronic conditions associated with an increased burden of SnC (obesity, diabetes, chronic lung or kidney disease, or cardiovascular disease).
Fig. 6 SASP Amplifier/Rheostat hypothesis. Schematic of the hypothesis generated from these data and tested herein. SnC amplified the response to PAMPs in vitro and in vivo, resulting in increased production of pro-inflammatory cytokines and chemokines. This could exacerbate acute systemic inflammatory responses and cytokine release by innate immune cells and amplify the spread of senescence. This model could explain the increased risk of cytokine storm during COVID-19 or other infections and adverse outcomes observed in the elderly or those with chronic conditions associated with an increased burden of SnC (obesity, diabetes, chronic lung or kidney disease, or cardiovascular disease).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

19 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 327

Metadata

Authors
Camell, C. D., Yousefzadeh, M. J., Zhu, Y., Prata, L. G. P. L., Huggins, M. A., Pierson, M., Zhang, L., O’Kelly, R. D., Pirtskhalava, T., Xun, P., Ejima, K., Xue, A., Tripathi, U., Espindola-Netto, J. M., Giorgadze, N., Atkinson, E. J., Inman, C. L., Johnson, K. O., Cholensky, S. H., Carlson, T. W., LeBrasseur, N. K., Khosla, S., O’Sullivan, M. G., Allison, D. B., Jameson, S. C., Meves, A., Li, M., Prakash, Y. S., Chiarella, S. E., Hamilton, S. E., Tchkonia, T., Niedernhofer, L. J., Kirkland, J. L., & Robbins, P. D.
Affiliations
  • University of Minnesota (US)
  • Mayo Clinic (US)
  • Institute on the Biology of Aging and Metabolism, Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.
  • Indiana University Bloomington (US)
  • Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, USA.
Corresponding author
  • Camell, Christina D.
  • Yousefzadeh, Matthew J.
  • Zhu, Yi
  • Prata, Larissa G. P. Langhi
  • Hamilton, Sara E.
  • Niedernhofer, Laura J.
  • Kirkland, James L.
  • Robbins, Paul D.
Venue
Science
Published
2021-07-16
Volume
373
Issue
6552
ISSN
  • 0036-8075 (ISSN-L)
  • 1095-9203
OpenAlex
W3172838821
Cited by
320
References
59
Citations by year
2026: 32 · 2025: 51 · 2024: 55 · 2023: 57 · 2022: 81 · 2021: 44
FWCI
37.23
Type
journal article
Language
en
Open access
Locations
  • Science (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Institute on Aging (AG063543-02S1, AG043376, AG056278, AG063543, AG062413, AG013925, AG058800)
  • University of Minnesota Clinical and Translational Science Institute (N/A)
  • Connor Fund (N/A)
  • Robert J. and Theresa W. Ryan Fund (N/A)
  • Noaber Foundation (N/A)
  • Glenn Foundation for Medical Research (N/A)
  • American Federation for Aging Research (N/A)
  • American Foundation for Aging Research
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Keywords
senolytics, cellular senescence, SARS-CoV-2, COVID-19 mortality, aging, inflammation, pathogen-associated molecular patterns, spike protein, antiviral gene expression, paracrine signaling, antiviral antibodies, age-related diseases
MeSH terms
Dasatinib, Pathogen-Associated Molecular Pattern Molecules, Receptors, Coronavirus, COVID-19, COVID-19 Drug Treatment, Aging, Animals, Cell Line, Female, Gene Expression Regulation, Murine hepatitis virus, Humans, Lipopolysaccharides, Male, Mice, Inbred C57BL, Quercetin, Specific Pathogen-Free Organisms, Cellular Senescence, Coronavirus Infections, Flavonols, Mice, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.